Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer

Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells – An updated review

(2018) Thingreila Muinao et al.   EXPERIMENTAL CELL RESEARCH

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

(2018) Gregory L. Beatty et al.   GASTROENTEROLOGY

Are ovarian cancer stem cells the target for innovative immunotherapy?

(2018) Liang Wang et al.   OncoTargets and Therapy

Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor–Based Immunotherapy and Chemotherapy

(2017) Rüdiger Klapdor et al.   HUMAN GENE THERAPY

CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways

(2017) Kiyoko Nakamura et al.   ONCOLOGY REPORTS

Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design

(2017) Fumou Sun et al.   Oncotarget

Increasing the safety and efficacy of chimeric antigen receptor T cell therapy

(2017) Hua Li et al.   Protein & Cell

Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment

(2017) Irene Scarfò et al.   Journal for ImmunoTherapy of Cancer

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits

(2016) Kole T. Roybal et al.   CELL

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells

(2016) Hans Klingemann et al.   Frontiers in Immunology

Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors

(2015) Julia D. Suerth et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

From Monoclonal Antibodies to Chimeric Antigen Receptors for the Treatment of Human Malignancies

(2014) Ignazio Caruana et al.   SEMINARS IN ONCOLOGY

Chronic Inflammation and Cytokines in the Tumor Microenvironment

(2014) Glauben Landskron et al.   Journal of Immunology Research

Are natural killer cells superior CAR drivers?

(2014) Hans Klingemann   OncoImmunology

CD24+ ovary cancer cells exhibit an invasive mesenchymal phenotype

(2013) Kyu Sub Kang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas

(2013) A V Salnikov et al.   BRITISH JOURNAL OF CANCER

Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells

(2013) M. Hudecek et al.   CLINICAL CANCER RESEARCH

Treatment of patients with advanced cancer with the natural killer cell line NK-92

(2013) Torsten Tonn et al.   CYTOTHERAPY

Ovarian cancer stem cells: Are they real and why are they important?

(2013) Monjri M. Shah et al.   GYNECOLOGIC ONCOLOGY

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

The Basic Principles of Chimeric Antigen Receptor Design

(2013) Michel Sadelain et al.   Cancer Discovery

Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo

(2013) E. Lanitis et al.   Cancer Immunology Research

Susceptibility of CD24+ ovarian cancer cells to anti-cancer drugs and natural killer cells

(2012) Jiae Koh et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells

(2012) Dongming Liang et al.   BMC CANCER

Ovarian cancer stem cell markers: Prognostic and therapeutic implications

(2012) Daniela Burgos-Ojeda et al.   CANCER LETTERS

Redirected T Cells That Target Pancreatic Adenocarcinoma Antigens Eliminate Tumors and Metastases in Mice

(2012) Amit Maliar et al.   GASTROENTEROLOGY

Cancerous ovarian stem cells: Obscure targets for therapy but relevant to chemoresistance

(2012) Nuzhat Ahmed et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

(2012) Scott Wilkie et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer

(2011) A. D. Steg et al.   CLINICAL CANCER RESEARCH

Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer

(2011) Philipp Harter et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile

(2011) Ardian Latifi et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor

(2011) Evripidis Lanitis et al.   MOLECULAR THERAPY

CD24: from A to Z

(2010) Xianfeng Fang et al.   Cellular & Molecular Immunology

Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen

(2010) A. A. Chekmasova et al.   CLINICAL CANCER RESEARCH

Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor

(2009) James N. Kochenderfer et al.   JOURNAL OF IMMUNOTHERAPY

Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication

(2009) Xiao-Song Zhong et al.   MOLECULAR THERAPY

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

(2008) S. Arai et al.   CYTOTHERAPY